JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board
JanOne Inc. (Nasdaq: JAN) announced the appointment of Dr. Nicholas E. Goeders to its Scientific Advisory Board. Dr. Goeders is a leading expert on stress and addiction, aiming to support JanOne's mission of developing non-addictive pain medications. CEO Tony Isaac emphasized Dr. Goeders' relevance as they advance their treatment for peripheral artery disease (PAD) into Phase 2b clinical trials. JanOne's lead candidate, JAN101, has shown promise in earlier trials, with plans for further development to address the pain and addiction risk associated with opioid prescriptions.
- Appointment of Dr. Nicholas E. Goeders enhances scientific expertise in addiction science.
- Positive results from the Phase 2a trial of JAN101, with Phase 2b trials upcoming.
- Focus on non-addictive pain medications aligns with industry needs.
- Concerns regarding the dependency on opioid prescriptions for treating severe PAD pain.
- Potential risks associated with the advancement in clinical trials.
LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board (SAB). Dr. Goeders is considered one of the world's leaders on the role of stress in drug addiction.
Tony Isaac, President and Chief Executive Officer of JanOne, commented, "JanOne's mission is to develop non-addictive medications to treat diseases that cause severe pain, thereby mitigating the use and abuse of harmful opioid painkillers. With his world-class reputation as a foremost expert in addiction science, Dr. Goeders is ideally suited to join our advisory team of scientific and medical experts in vascular pathophysiology, including peripheral artery disease (PAD), and pain management across a broad range of chronic diseases and disorders. We are excited to welcome Dr. Goeders to our SAB at this important stage in our Company's history as we advance our treatment for PAD into Phase 2b clinical trials."
Tony Giordano, Ph.D., Chief Scientific Officer of JanOne, added, "Dr. Goeders' dedication to the field of addition has produced research and findings that are virtually unmatched in scope and consequence. He will be an outstanding addition to our esteemed Scientific Advisory Board."
Dr. Goeders is professor and head of the Department of Pharmacology, Toxicology and Neuroscience at Louisiana State University (LSU) Health Sciences Center Shreveport, where he has been a member of the faculty since 1985. He is also a co-founder of Embera NeuroTherapeutics, Inc., developer of a novel pharmacotherapy treatment for substance use disorders that is based on results from his research on stress and addiction. Prior to 1985, Dr. Goeders was a Staff Fellow of the National Institute on Drug Abuse (NIDA) at the Addiction Research Center in Baltimore, Maryland and a Postdoctoral Fellow at The Johns Hopkins University School of Medicine, Department of Neuroscience. He received his Doctor of Philosophy from the Louisiana State University Medical Center with a major in Pharmacology. Dr. Goeders holds seven patents based on his research which has been actively funded by the National Institutes of Health (NIH) since 1983. He has published 115 scientific papers in peer-reviewed journals and has presented the results of his research worldwide. He is a member of the American College of Neuropsychopharmacology, a former member of the Board of Directors and a current Fellow of the College on Problems of Drug Dependence, the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics, the Behavioral Pharmacology Society, and the Society for Neuroscience.
"I am delighted to be able to contribute my knowledge to the very important work JanOne is doing to reduce risk associated with opioid addiction and overdose," said Dr. Goeders. "PAD associated pain can be severe, and nearly
Additional members of JanOne's Scientific Advisory Board include:
- Chris Kevil, Ph.D., Chair of the Scientific Advisory Board -- Vice Chancellor for Research, Dean School of Graduate Studies, and Malcolm Feist Endowed Chair for Cardiovascular Disease at LSU Health Shreveport.
- Edgar Ross, MD -- Director of the Pain Management Center at Brigham and Women's Hospital and a professor of anesthesia at Harvard Medical School.
- John Cooke, MD, Ph.D. -- Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center in Houston, Texas.
- Joshua Beckman, MD, MS -- Professor of Medicine at Vanderbilt Medical School, and Director of the Section of Vascular Medicine at Vanderbilt University Medical Center.
About JanOne
JanOne (Nasdaq: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate, JAN101, is for potentially treating peripheral artery disease ("PAD"), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in the near future. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions, and neuropathic pain. For more information, visit www.janone.com.
Forward-Looking and Cautionary Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that include everything other than historical information, including statements relating to the commencement of the upcoming Phase 2b trials, whether JAN101 can treat other conditions involving vascular complications, including chronic kidney disease. These forward-looking statements can be identified by terminology such as "will," "aims," "upcoming," "may," "expects," "expected," "potential," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. JanOne may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC") on Forms 10-K and 10-Q, Current Reports on Form 8-K, in its annual report to stockholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the company, including, but not limited to, plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report on Form 10-K for the fiscal year ended January 2, 2021 and other SEC filings (available at http://www.sec.gov). JanOne undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Investor Relations & Media Contact
IR@Janone.com
1 (800) 400-2247
View original content to download multimedia:http://www.prnewswire.com/news-releases/janone-appoints-internationally-renowned-expert-on-addiction-nicholas-goeders-phd-to-scientific-advisory-board-301310672.html
SOURCE JanOne Inc.
FAQ
What is the significance of Dr. Nicholas E. Goeders' appointment to JanOne's Scientific Advisory Board?
What clinical trials are planned for JanOne's lead candidate, JAN101?
How does JanOne address the issue of opioid addiction?
What are the potential risks highlighted in the press release for JanOne?
